Toll Free: 1-888-928-9744
Published: Jul, 2016 | Pages:
55 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Panacea Biotec Limited - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'Panacea Biotec Limited - Product Pipeline Review - 2016', provides an overview of the Panacea Biotec Limited's pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Panacea Biotec Limited, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of Panacea Biotec Limited - The report provides overview of Panacea Biotec Limited including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses Panacea Biotec Limited's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features Panacea Biotec Limited's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons To Buy - Evaluate Panacea Biotec Limited's strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Panacea Biotec Limited - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Panacea Biotec Limited's pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Panacea Biotec Limited Snapshot 7 Panacea Biotec Limited Overview 7 Key Information 7 Key Facts 7 Panacea Biotec Limited - Research and Development Overview 8 Key Therapeutic Areas 8 Panacea Biotec Limited - Pipeline Review 12 Pipeline Products by Stage of Development 12 Pipeline Products - Monotherapy 13 Pipeline Products - Combination Treatment Modalities 14 Panacea Biotec Limited - Pipeline Products Glance 15 Panacea Biotec Limited - Late Stage Pipeline Products 15 Phase III Products/Combination Treatment Modalities 15 Panacea Biotec Limited - Clinical Stage Pipeline Products 16 Phase II Products/Combination Treatment Modalities 16 Phase I Products/Combination Treatment Modalities 17 Panacea Biotec Limited - Early Stage Pipeline Products 18 Preclinical Products/Combination Treatment Modalities 18 Discovery Products/Combination Treatment Modalities 19 Panacea Biotec Limited - Unknown Stage Pipeline Products 20 Unknown Products/Combination Treatment Modalities 20 Panacea Biotec Limited - Drug Profiles 21 (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + polio + tetanus) (hexavalent) vaccine 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 (diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole cell) + polio + tetanus)(pentavalent) vaccine 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 polio [strain Sabin] vaccine 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 Nucovac 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 bevacizumab biosimilar 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 cetuximab biosimilar 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 darbepoetin alfa 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 etanercept biosimilar 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 hepatitis B vaccine 2 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Monoclonal Antibodies for Cancer 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 omalizumab biosimilar 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 rituximab biosimilar 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Synthetic Peptide for Alopecia 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 trastuzumab biosimilar 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 dengue (tetravalent) vaccine 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 influenza vaccine 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Japanese encephalitis vaccine 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 meningococcal vaccine 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 pertussis (acellular) vaccine 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 pneumococcal vaccine 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 respiratory syncytial virus vaccine 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Synthetic Peptides to Agonize GLP-1 for Type 2 Diabetes 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 yellow fever vaccine 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 Recombinant Protein for Autoimmune Disorders 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 Recombinant Protein for Renal Anemia 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 Panacea Biotec Limited - Pipeline Analysis 46 Panacea Biotec Limited - Pipeline Products by Target 46 Panacea Biotec Limited - Pipeline Products by Route of Administration 47 Panacea Biotec Limited - Pipeline Products by Molecule Type 48 Panacea Biotec Limited - Pipeline Products by Mechanism of Action 49 Panacea Biotec Limited - Recent Pipeline Updates 50 Panacea Biotec Limited - Dormant Projects 51 Panacea Biotec Limited - Company Statement 52 Panacea Biotec Limited - Locations And Subsidiaries 53 Head Office 53 Other Locations & Subsidiaries 53 Appendix 54 Methodology 54 Coverage 54 Secondary Research 54 Primary Research 54 Expert Panel Validation 54 Contact Us 54 Disclaimer 55
List of Tables
Panacea Biotec Limited, Key Information 7 Panacea Biotec Limited, Key Facts 7 Panacea Biotec Limited - Pipeline by Indication, 2016 9 Panacea Biotec Limited - Pipeline by Stage of Development, 2016 12 Panacea Biotec Limited - Monotherapy Products in Pipeline, 2016 13 Panacea Biotec Limited - Combination Treatment Modalities in Pipeline, 2016 14 Panacea Biotec Limited - Phase III, 2016 15 Panacea Biotec Limited - Phase II, 2016 16 Panacea Biotec Limited - Phase I, 2016 17 Panacea Biotec Limited - Preclinical, 2016 18 Panacea Biotec Limited - Discovery, 2016 19 Panacea Biotec Limited - Unknown, 2016 20 Panacea Biotec Limited - Pipeline by Target, 2016 46 Panacea Biotec Limited - Pipeline by Route of Administration, 2016 47 Panacea Biotec Limited - Pipeline by Molecule Type, 2016 48 Panacea Biotec Limited - Pipeline Products by Mechanism of Action, 2016 49 Panacea Biotec Limited - Recent Pipeline Updates, 2016 50 Panacea Biotec Limited - Dormant Developmental Projects,2016 51 Panacea Biotec Limited, Other Locations 53 Panacea Biotec Limited, Subsidiaries 53
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.